| Name | Title | Contact Details |
|---|---|---|
Sam Winikoff |
Director of Compliance and Legal Affairs | Profile |
Michigan Institute-Health Enhn is a Rochester Hills, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Assisted Living-Madison House is a Kirkland, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For more than 20 years, Fortus Healthcare Resources has embraced a personalized approach to recruiting. With a candidate database unmatched in the industry, we value our relationship with clients and candidates. The Fortus Group is the pioneer of dialysis recruitment. Since 1993, we have been committed to providing recruitment solutions for the dialysis industry with much success and growth. Our organization has expanded from a one-desk specialty recruiter to a state-of-the-art facility. With a staff of over 30, we continue to maintain the largest recruiting staff industrywide. Our company`s 100+ years combined dialysis recruiting experience enables us to provide the best possible means for candidates to fulfill their goals. In 2006, our services expanded from permanent placement of dialysis and transplantation professionals to the placement of travel nurses. With flexible, competitive salary and benefit packages, Fortus Group Travel offers the healthcare industry temporary staffing relief, while providing nurses with unlimited travel opportunities. The Fortus Group continues to build on its strong foundation of quality resources and dedicated relationships. The success of our company is based on bringing together the highest quality career consultants dedicated to providing outstanding opportunities to our specialized industry.
Synteract, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig`s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.